Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

M. Macchini; E. Garralda; W. Fiedler; G. Del Conte; C. Rolling; M. Kebenko; K. F. Klinghammer; I. Ahrens-fath; B. Habel; H. Baumeister; A. Zurlo; S. Ochsenreiter

doi:10.1016/S0959-8049(20)31083-2

Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

M. Macchini, E. Garralda, W. Fiedler, G. Del Conte, C. Rolling, M. Kebenko, K. F. Klinghammer, I. Ahrens-fath, B. Habel, H. Baumeister, A. Zurlo, S. Ochsenreiter

Department of Hematology and Oncology

Original language	English
Journal	European Journal of Cancer
Volume	138
Pages (from-to)	S5-S6
ISSN	0959-8049
DOIs	https://doi.org/10.1016/S0959-8049(20)31083-2
Publication status	Published - 10.2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0959-8049(20)31083-2

Cite this

Macchini, M., Garralda, E., Fiedler, W., Del Conte, G., Rolling, C., Kebenko, M., Klinghammer, K. F., Ahrens-fath, I., Habel, B., Baumeister, H., Zurlo, A., & Ochsenreiter, S. (2020). Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors. European Journal of Cancer, 138, S5-S6. https://doi.org/10.1016/S0959-8049(20)31083-2

@article{affd8505d42649f78c72ddaa2a232233,

title = "Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors",

author = "M. Macchini and E. Garralda and W. Fiedler and \{Del Conte\}, G. and C. Rolling and M. Kebenko and Klinghammer, \{K. F.\} and I. Ahrens-fath and B. Habel and H. Baumeister and A. Zurlo and S. Ochsenreiter",

year = "2020",

month = oct,

doi = "10.1016/S0959-8049(20)31083-2",

language = "English",

volume = "138",

pages = "S5--S6",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

Macchini, M, Garralda, E, Fiedler, W, Del Conte, G, Rolling, C, Kebenko, M, Klinghammer, KF, Ahrens-fath, I, Habel, B, Baumeister, H, Zurlo, A & Ochsenreiter, S 2020, 'Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors', European Journal of Cancer, vol. 138, pp. S5-S6. https://doi.org/10.1016/S0959-8049(20)31083-2

Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors. / Macchini, M.; Garralda, E.; Fiedler, W. et al.
In: European Journal of Cancer, Vol. 138, 10.2020, p. S5-S6.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

AU - Macchini, M.

AU - Garralda, E.

AU - Fiedler, W.

AU - Del Conte, G.

AU - Rolling, C.

AU - Kebenko, M.

AU - Klinghammer, K. F.

AU - Ahrens-fath, I.

AU - Habel, B.

AU - Baumeister, H.

AU - Zurlo, A.

AU - Ochsenreiter, S.

PY - 2020/10

Y1 - 2020/10

UR - https://www.scopus.com/pages/publications/85093659697

U2 - 10.1016/S0959-8049(20)31083-2

DO - 10.1016/S0959-8049(20)31083-2

M3 - Journal articles

AN - SCOPUS:85093659697

SN - 0959-8049

VL - 138

SP - S5-S6

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Macchini M, Garralda E, Fiedler W, Del Conte G, Rolling C, Kebenko M et al. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors. European Journal of Cancer. 2020 Oct;138:S5-S6. doi: 10.1016/S0959-8049(20)31083-2

Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

UN SDGs

Access to Document

Other files and links

Cite this